-
Chinese medicine production license was cancelled
Time of Update: 2021-08-14
On August 6, the official website of the Chongqing Drug Administration showed that the drug production license of Traditional Chinese Medicine was cancelled .
Attachment: the content of the cancelled license
-
After the expiration of the national procurement, the price of cephalexin renewed bid soared by nearly 90%?
Time of Update: 2021-08-14
Source: Shanxi Province Pharmaceutical Equipment Centralized Bidding and Purchasing CenterCephalexin oral normal-release dosage form is the product selected by the exclusive enterprise in the second batch of national centralized drug procurement.
-
Anke Biotech's PA3-17 injection was approved for clinical use
Time of Update: 2021-08-14
On August 9th, Anke Biological issued an announcement stating that its shareholding company, Boshengji, received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration, agreeing to carry out the treatment of adult relapsed/refractory CD7 positive blood Clinical trials for malignant tumors of the lymphatic system .
-
Tengshengbo's new coronary pneumonia neutralizing antibody combination therapy phase III study is completed and enrolled
Time of Update: 2021-08-14
On August 5, Tengshengbo Pharmaceutical announced that its monoclonal neutralizing antibody BRII-196/BRII-198 combination therapy phase III ACTIV-2 study has completed 846 subjects in research centers in the United States, Brazil, South Africa, Mexico and Argentina Join the group .
-
The Phase II clinical trial of Golly Pharmaceuticals ASC40 for the treatment of acne was approved by the State Food and Drug Administration
Time of Update: 2021-08-14
On August 9, Golly Pharmaceuticals announced that China's National Medical Products Administration has approved the launch of ASC40 in the treatment of patients with moderate and severe acne phase II clinical trials .
-
Medical insurance big action: the collection of large-scale medical equipment is coming
Time of Update: 2021-08-14
Since in April this year, the implementation plan for centralized procurement issued by the Anhui Medical Insurance Bureau clearly stated that "adhere to the principle of purchasing with quantity and changing prices with quantity", the industry interpretation believes that the centralized procurement of large-scale medical equipment with quantity is coming .
-
EQRx is about to land on Nasdaq Cornerstone Pharmaceuticals Shuglizumab contributes three-quarters of the valuation
Time of Update: 2021-08-14
(NASDAQ: CMLTU) jointly announced that the two parties have reached an agreement on a final business merger agreement.
After the business merger in the fourth quarter of this year, CM Life Sciences III will Renamed "EQRx, Inc.
65 billion, and another performance valuation of US$500 million .
-
WHO: 203,295,170 confirmed cases of new crowns worldwide
Time of Update: 2021-08-13
The latest data from the WHO website shows that as of 18:22 on the 10th Central European Time (0:22 on the 11th, Beijing time), the number of confirmed cases worldwide increased by 560,850 compared with the previous day, reaching 203,295,170; the number of deaths increased by 8,426.
Focus on the new crown pneumonia epidemic
-
National Health Commission: 71 new local cases on the 3rd, involving 7 places
Time of Update: 2021-08-13
As of 24:00 on August 3, according to reports from 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps, there are 1,240 confirmed cases (including 21 severe cases), 87,413 cured and discharged cases, and 4,636 deaths.
-
Interview: New Coronavirus "Laboratory Leak Theory" Cannot Withstand Scientific Scrutiny
Time of Update: 2021-08-13
In response to some conspiracy theorists claiming that the RaTG13 coronavirus may be the source of the new coronavirus, Robertson said that the coronavirus isolated from Yunnan bats by researchers at the Wuhan Institute of Virology is very different from the new coronavirus, with about 1,100 mutations.
-
Clinical trials of two domestically-made new crown vaccines mixed with "enhanced injection" approved
Time of Update: 2021-08-13
According to news from Ai Di Weixin on August 9, Ai Di Weixin's new crown DNA vaccine (INO-4800/pGX9501) has been approved to conduct clinical trials with inactivated vaccines to explore sequential immunization strategies .
-
The global cumulative number of confirmed cases of new crown reached 202,608,306
Time of Update: 2021-08-13
Reached 4,293,591 cases .
-
On August 9th, Beijing reported 1 exceptional case of pulmonary anthrax in Beijing
Time of Update: 2021-08-13
Anthrax is an infectious disease caused by bacteria (Bacillus anthracis), which is mainly prevalent in herbivorous animals such as cattle, sheep, and deer .
Humans are generally infected with anthrax through contact with animals and their products infected with anthrax.
-
Japanese experts found that the delta mutant strain may be more pathogenic
Time of Update: 2021-08-13
According to a report by the Japan Broadcasting Association (NHK) on the 3rd, a research team composed of the University of Tokyo in Japan published the latest research on the delta variant of the new crown virus.
-
Disease control experts: Hubei's current round of epidemic has three characteristics
Time of Update: 2021-08-13
The epidemic, the same source of transmission, a single chain of transmission, all subsequent infections have three characteristics found in the investigation within the scope of isolation, control, and circulation .
-
The State Food and Drug Administration issued a notice that 18 batches of drugs did not meet the requirements
Time of Update: 2021-08-13
After inspection by Hubei Provincial Institute of Drug Supervision and Inspection, a batch of Atractylodes japonicus (fried atractylodes with bran) produced by Anhui Wukeng Chinese Medicine Decoction Pieces Co.
-
Gloria's market value exceeds 100 billion Kanglong and doubles in the year. Will the CXO industry usher in the top of the cycle?
Time of Update: 2021-08-13
Since WuXi AppTec had a good increase in the previous period, the valuation was also the first to appear at a premium; and like Kanglong Chemical, Because of the rapid growth of the performance of the second-tier standards such as Kailaiying, the high growth rate can enjoy a higher valuation level, so the share prices of second-tier CXO companies have generally hit new highs year-to-date .
-
WHO: A total of 200,174,883 confirmed cases of new crowns worldwide
Time of Update: 2021-08-13
According to the latest data from the WHO website, as of 18:08 on the 5th Central European Time (0:08 on the 6th Beijing time), the number of confirmed cases worldwide increased by 658,630 compared with the previous day, reaching 200,174,883; the number of deaths increased by 10,215.
-
More than 200 million delta strains of new crowns diagnosed globally are raging in many countries
Time of Update: 2021-08-13
Iran is currently suffering from the fifth wave of the epidemic, the delta strain is spreading across the country, and the number of newly confirmed cases in a single day has repeatedly hit record highs .
-
Negative growth for the first time in the past 5 years!
Time of Update: 2021-08-13
The sales scale of the terminal diabetic chemical drug market in physical pharmacies in cities in China (100 million yuan)Source: Mi Nei. com, China's urban physical pharmacy terminal competition patternSales of half of the top 10 non-insulin hypoglycemic drugs declined year-on-yearSales of half of the top 10 non-insulin hypoglycemic drugs declined year-on-yearIn 2020, the market share of TOP10 non-insulin hypoglycemic drugs totaled 71.